Natco Pharma Canada Inc. launches ^PrNAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid®

Natco Pharma (Canada) Inc., a subsidiary of Natco Pharma Limited, announced today the launch of ^PrNAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid® to be approved by Health Canada.

^PrNAT-LENADLIDOMIDE is used in combination with dexamethasone for the treatment of multiple myeloma in patients who are not eligible for stem cell transplant. ^PrNAT-LENALIDOMIDE is also indicated for treatment of transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion of 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

"We are proud to have led the way for an accessible treatment option for multiple myeloma that may alleviate the financial burden for myeloma patients, as well as public and private payers," said Glenn Ikeda, Ph.D., CEO of Natco Pharma (Canada) Inc. "Our team has been working diligently to improve the supply of accessible, high-quality medicines to Canadian patients. The launch of ^PrNAT-LENALIDOMIDE represents an important milestone in Natco's continued efforts to expand its product portfolio and is the result of considerable Canadian investment that will bring cost savings to healthcare at a critical time."

Sales of oncology medicines have nearly tripled over the past decade with a shift towards higher-cost drugs1. Multiple myeloma, commonly referred to as myeloma, is a cancer of plasma cells and the second most common form of blood cancer2. Patients with this type of cancer may have low blood cell counts and immune problems giving them a higher chance for getting infections such as pneumonia. The bones can be affected leading to bone pain and breaks (fractures)3. About 7,400 Canadians are living with or are in remission from myeloma4 and every day, 9 Canadians are diagnosed with the disease5. To date there is no cure for myeloma, however several types of treatments help control the disease.

"As a self-administered capsule, lenalidomide is an important therapy for Canadian patients whose lives are critically impacted by a variety of myeloma-related events and symptoms. This treatment aims at prolonging survival and improving quality of life. The availability of NAT-LENALIDOMIDE as the first generic alternative to Revlimid® is excellent news," commented Joe Kamel, Registered Pharmacist, at Pure Health Pharmacy in Barrie, Ontario.

^r NAT-LENALIDOMIDE is available through the RevAid® risk management plan in strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules.

Shares of Natco Pharma Ltd. was last trading in BSE at Rs. 939.45 as compared to the previous close of Rs. 944.25. The total number of shares traded during the day was 155313 in over 703 trades.

The stock hit an intraday high of Rs. 948 and intraday low of 923. The net turnover during the day was Rs. 144386831.

Source : Equity Bulls

Keywords